» Articles » PMID: 11986316

Opposing Action of Estrogen Receptors Alpha and Beta on Cyclin D1 Gene Expression

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2002 May 3
PMID 11986316
Citations 143
Authors
Affiliations
Soon will be listed here.
Abstract

Induction of cyclin D1 gene transcription by estrogen receptor alpha (ERalpha) plays an important role in estrogen-mediated proliferation. There is no classical estrogen response element in the cyclin D1 promoter, and induction by ERalpha has been mapped to an alternative response element, a cyclic AMP-response element at -57, with possible participation of an activating protein-1 site at -954. The action of ERbeta at the cyclin D1 promoter is unknown, although evidence suggests that ERbeta may inhibit the proliferative action of ERalpha. We examined the response of cyclin D1 promoter constructs by luciferase assay and the response of the endogenous protein by Western blot in HeLa cells transiently expressing ERalpha, ERalphaK206A (a derivative that is superactive at alternative response elements), or ERbeta. In each case, ER activation at the cyclin D1 promoter is mediated by both the cyclic AMP-response element and the activating protein-1 site, which play partly redundant roles. The activation by ERbeta occurs only with antiestrogens. Estrogens, which activate cyclin D1 gene expression with ERalpha, inhibit expression with ERbeta. Strikingly, the presence of ERbeta completely inhibits cyclin D1 gene activation by estrogen and ERalpha or even by estrogen and the superactive ERalphaK206A. The observation of the opposing action and dominance of ERbeta over ERalpha in activation of cyclin D1 gene expression has implications for the postulated role of ERbeta as a modulator of the proliferative effects of estrogen.

Citing Articles

Impact of Estrogen on Purinergic Signaling in Microvascular Disease.

Cassavaugh J, Longhi M, Robson S Int J Mol Sci. 2025; 26(5).

PMID: 40076726 PMC: 11900469. DOI: 10.3390/ijms26052105.


Menopausal status-dependent alterations in the transcript levels of genes encoding ERα, ERβ, PR and HER2 in breast tumors with different receptor status.

Berkel C Clin Transl Oncol. 2024; .

PMID: 39495410 DOI: 10.1007/s12094-024-03777-x.


Cellular and molecular events in colorectal cancer: biological mechanisms, cell death pathways, drug resistance and signalling network interactions.

Yan L, Shi J, Zhu J Discov Oncol. 2024; 15(1):294.

PMID: 39031216 PMC: 11265098. DOI: 10.1007/s12672-024-01163-1.


Mitigation of letrozole induced polycystic ovarian syndrome associated inflammatory response and endocrinal dysfunction by Vitex negundo seeds.

Kar T, Sil S, Ghosh A, Barman A, Chattopadhyay S J Ovarian Res. 2024; 17(1):76.

PMID: 38589892 PMC: 11000293. DOI: 10.1186/s13048-024-01378-4.


Protecting the Brain: Novel Strategies for Preventing Breast Cancer Brain Metastases through Selective Estrogen Receptor β Agonists and In Vitro Blood-Brain Barrier Models.

Kirchner J, Volker E, Shityakov S, Saji S, Forster C Int J Mol Sci. 2024; 25(6).

PMID: 38542355 PMC: 10970534. DOI: 10.3390/ijms25063379.